HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for COVID-19

Don’t Get Caught In Long-COVID OTC Painkiller ‘Hamster Wheel,’ Warn German Neurologists

A significant proportion of COVID-19 headache sufferers go on to develop “new daily persistent headaches” syndrome. German neurologists warn that these people are at danger of medication overuse headaches, as well as kidney damage, as a result of taking OTC analgesics on a daily basis. 

International Germany

Along With Sales Across Regions And Categories, Perrigo’s Labor Shortage Concerns Grow

“The only thing that keeps me up at night right now is labor shortages,” says CEO Murray Kessler. He also notes growing trend of consumers responding to inflation by moving from national brands to lower-priced private label/store brand OTC drugs.

Supply Chain Coronavirus COVID-19

Prestige Consumer Opens Its FY2023 With Revenue Thirst Quenched By Hydralyte International Sales

Hydralyte line has 90% share in Australia’s hydration market and accounted for a large share of firm’s overall sales growth in its latest quarter as 28.9% international sales growth to $34.5m offset flat North American results at $242.4m.

Sales & Earnings Companies

CPHI Podcast Special: The Supplements Market – From Slump to Surge

In this podcast special, HBW Insight senior editor David Ridley is interviewed by CPHI's Rebecca Lumley about the latest trends in the European dietary supplements space. They discuss which products surged in popularity during the pandemic, the rise of self-care and the current regulatory environment in Europe.

Europe Wellness

Inflation And COVID Putting Pressure On Europe’s Paracetamol Supply Chain

Inflation, new COVID-19 waves and delayed cold and flu outbreaks are causing disruption to Europe's paracetamol supply chain, according to an investigation by HBW Insight. Industry is not currently concerned, but regulators, for example in France, are introducing measures to prevent this issue spreading from children's to adult forms of the drug, as well as to ibuprofen-based alternatives.

Europe Germany

US FDA Explains How It Is Embracing Remote Assessments Post-Pandemic

Agency provides additional details on plans for various remote methods of assessing Rx and OTC drug manufacturing facilities that became popular when investigators were prevented by COVID-19 travel restrictions from visiting sites in person.

Coronavirus COVID-19 FDA

J&J Consumer Health Q2 Results No Help For Avoiding Lowering Full-Year Guidance Again

J&J reported lower consumer health sales during its latest quarter; consumer health businesses name and branding to be announced in the next few months.

Sales & Earnings M & A

USANA’s Preliminary Earnings Alert Could Signal Trend In Q2 Results Across Consumer Health

Pandemic-related market lockdowns, shipping backlogs and other disruptions in mainland China and other countries USANA referenced in announcement also could affect results for its direct-selling competitors as well as other firms in health, wellness, personal care and beauty industries.

Consumer Supply Chain
See All